ES2240526T3 - Composicion farmaceutica para inmunizar contra el sida. - Google Patents

Composicion farmaceutica para inmunizar contra el sida.

Info

Publication number: ES2240526T3
Authority: ES; Spain
Prior art keywords: mug; antigen; hiv; igg; dcchol
Prior art date: 2000-10-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES01976378T

Other languages

English (en)

Spanish (es)

Inventor

Jean Haensler

Francois Dalencon

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Pasteur Inc

Original Assignee

Sanofi Pasteur Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-06

Filing date

2001-10-08

Publication date

2005-10-16

2001-10-08 Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc

2005-10-16 Application granted granted Critical

2005-10-16 Publication of ES2240526T3 publication Critical patent/ES2240526T3/es

2021-10-08 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
208000030507 AIDS Diseases 0.000 title description 7
102000036639 antigens Human genes 0.000 claims abstract description 55
108091007433 antigens Proteins 0.000 claims abstract description 55
239000000427 antigen Substances 0.000 claims abstract description 53
230000003053 immunization Effects 0.000 claims abstract description 30
238000002649 immunization Methods 0.000 claims abstract description 22
239000003814 drug Substances 0.000 claims abstract description 7
208000015181 infectious disease Diseases 0.000 claims abstract description 6
238000002360 preparation method Methods 0.000 claims abstract description 4
108091034117 Oligonucleotide Proteins 0.000 claims description 17
101710149951 Protein Tat Proteins 0.000 claims description 16
239000000839 emulsion Substances 0.000 claims description 8
230000003308 immunostimulating effect Effects 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 4
230000006698 induction Effects 0.000 claims description 4
210000004400 mucous membrane Anatomy 0.000 claims description 3
210000001519 tissue Anatomy 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims 1
239000000203 mixture Substances 0.000 description 44
229960005486 vaccine Drugs 0.000 description 22
241000725303 Human immunodeficiency virus Species 0.000 description 19
230000004044 response Effects 0.000 description 17
238000000034 method Methods 0.000 description 14
101710205625 Capsid protein p24 Proteins 0.000 description 13
101710177166 Phosphoprotein Proteins 0.000 description 13
101710149279 Small delta antigen Proteins 0.000 description 13
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 13
108090000623 proteins and genes Proteins 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
241000699670 Mus sp. Species 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
239000013598 vector Substances 0.000 description 10
230000028327 secretion Effects 0.000 description 9
210000002966 serum Anatomy 0.000 description 9
241000713772 Human immunodeficiency virus 1 Species 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
230000000694 effects Effects 0.000 description 8
238000002965 ELISA Methods 0.000 description 7
239000013604 expression vector Substances 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
208000031886 HIV Infections Diseases 0.000 description 6
241000700605 Viruses Species 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
101800001690 Transmembrane protein gp41 Proteins 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
239000002671 adjuvant Substances 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000001939 inductive effect Effects 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000028993 immune response Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
239000000047 product Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
238000012360 testing method Methods 0.000 description 4
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
108090000288 Glycoproteins Proteins 0.000 description 3
102000003886 Glycoproteins Human genes 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
101150014732 asnS gene Proteins 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000003756 cervix mucus Anatomy 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000000243 solution Substances 0.000 description 3
229940031439 squalene Drugs 0.000 description 3
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
239000000725 suspension Substances 0.000 description 3
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000700198 Cavia Species 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
101710204610 Envelope glycoprotein gp160 Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
208000031957 HIV carrier Diseases 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008038 Synthetic Vaccines Proteins 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
QNEPTKZEXBPDLF-JDTILAPWSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] carbonochloridate Chemical compound C1C=C2C[C@@H](OC(Cl)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QNEPTKZEXBPDLF-JDTILAPWSA-N 0.000 description 2
HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000011210 chromatographic step Methods 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
230000008348 humoral response Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
229960001438 immunostimulant agent Drugs 0.000 description 2
239000003022 immunostimulating agent Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000013642 negative control Substances 0.000 description 2
230000003472 neutralizing effect Effects 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
229940124551 recombinant vaccine Drugs 0.000 description 2
238000005070 sampling Methods 0.000 description 2
230000007017 scission Effects 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
238000011282 treatment Methods 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
101710177291 Gag polyprotein Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
241000282553 Macaca Species 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
241000288906 Primates Species 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000000240 adjuvant effect Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229940023860 canarypox virus HIV vaccine Drugs 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000001571 immunoadjuvant effect Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940088592 immunologic factor Drugs 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000012212 insulator Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000005906 menstruation Effects 0.000 description 1
239000000693 micelle Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 1
HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Immunology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
Motorcycle And Bicycle Frame (AREA)
Superconductors And Manufacturing Methods Therefor (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Compounds Of Unknown Constitution (AREA)

ES01976378T 2000-10-06 2001-10-08 Composicion farmaceutica para inmunizar contra el sida. Expired - Lifetime ES2240526T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0012808A FR2814958B1 (fr)	2000-10-06	2000-10-06	Composition vaccinale
FR0012808		2000-10-06

Publications (1)

Publication Number	Publication Date
ES2240526T3 true ES2240526T3 (es)	2005-10-16

Family

ID=8855083

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
ES01976378T Expired - Lifetime ES2240526T3 (es)	2000-10-06	2001-10-08	Composicion farmaceutica para inmunizar contra el sida.
ES01976380T Expired - Lifetime ES2275738T3 (es)	2000-10-06	2001-10-08	Composicion vacunal.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
ES01976380T Expired - Lifetime ES2275738T3 (es)	2000-10-06	2001-10-08	Composicion vacunal.

Country Status (12)

Country	Link
US (3)	US20030190326A1 (de)
EP (2)	EP1326636B1 (de)
AT (2)	ATE350057T1 (de)
AU (2)	AU2001295671A1 (de)
CA (1)	CA2424836A1 (de)
CY (1)	CY1105943T1 (de)
DE (2)	DE60110822T2 (de)
DK (1)	DK1326636T3 (de)
ES (2)	ES2240526T3 (de)
FR (1)	FR2814958B1 (de)
PT (2)	PT1326636E (de)
WO (2)	WO2002028427A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6727230B1 (en) *	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
EP0855184A1 (de) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
SI1077722T1 (sl)	1998-05-22	2007-02-28	Ottawa Health Research Inst	Metode in produkti za induciranje sluznicne imunosti
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) *	1998-06-25	2004-02-17	National Jewish Medical And Research Center	Systemic immune activation method using nucleic acid-lipid complexes
ES2572834T3 (es)	1999-02-17	2016-06-02	Csl Limited	Complejos inmunogénicos y métodos relacionados con los mismos
US20050226890A1 (en) *	1999-08-12	2005-10-13	Cohen David I	Tat-based vaccine compositions and methods of making and using same
NZ520976A (en) *	1999-11-19	2005-01-28	Csl Ltd	Vaccine compositions
US20010044416A1 (en) *	2000-01-20	2001-11-22	Mccluskie Michael J.	Immunostimulatory nucleic acids for inducing a Th2 immune response
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
KR100917101B1 (ko) *	2000-08-04	2009-09-15	도요 보세키 가부시키가이샤	플렉시블 금속적층체 및 그 제조방법
US20080044435A1 (en) *	2004-03-16	2008-02-21	Cohen David I	Tat-Based Tolerogen Compositions and Methods of Making and Using Same
ATE411054T1 (de) *	2001-08-17	2008-10-15	Coley Pharm Gmbh	Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
US7569553B2 (en) *	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en)	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en)	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en)	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) *	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
CN1753687A (zh) *	2002-10-29	2006-03-29	科勒制药集团股份有限公司	Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
CA2502015A1 (en)	2002-12-11	2004-06-24	Coley Pharmaceutical Group, Inc.	5' cpg nucleic acids and methods of use
AU2004226605A1 (en) *	2003-04-02	2004-10-14	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
US20050013812A1 (en) *	2003-07-14	2005-01-20	Dow Steven W.	Vaccines using pattern recognition receptor-ligand:lipid complexes
AU2004275876B2 (en) *	2003-09-25	2011-03-31	Coley Pharmaceutical Gmbh	Nucleic acid-lipophilic conjugates
US7927580B2 (en) *	2004-03-16	2011-04-19	Nanirx, Inc.	Tat-based immunomodulatory compositions and methods of their discovery and use
TWI235440B (en) *	2004-03-31	2005-07-01	Advanced Semiconductor Eng	Method for making leadless semiconductor package
US20060287263A1 (en) *	2004-07-18	2006-12-21	Csl Limited	Methods and compositions for inducing antigen-specific immune responses
FR2881050B1 (fr) *	2005-01-25	2007-02-23	Sanofi Pasteur Sa	Dcchol chez les nouveaux-nes
US20060165717A1 (en) *	2005-01-25	2006-07-27	Sanofi Pasteur	DCchol in newborns
KR20080030656A (ko) *	2005-07-07	2008-04-04	콜레이 파마시티컬 그룹, 인코포레이티드	암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법
PT2078080E (pt)	2006-09-27	2015-09-18	Coley Pharm Gmbh	Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
EP2411043B1 (de)	2009-03-23	2013-07-31	PIN Pharma, Inc.	Krebsbehandlung mit immunstimulierenden hiv-tat-derivat-polypeptiden
CN105705164A (zh)	2013-10-04	2016-06-22	品诺制药公司	用于癌症治疗的免疫刺激性hiv tat衍生多肽

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1502774A (en) *	1974-06-25	1978-03-01	Nat Res Dev	Immunological preparations
US5100662A (en) *	1989-08-23	1992-03-31	The Liposome Company, Inc.	Steroidal liposomes exhibiting enhanced stability
US5283185A (en) *	1991-08-28	1994-02-01	University Of Tennessee Research Corporation	Method for delivering nucleic acids into cells
FR2732605B1 (fr) *	1995-04-07	1997-05-16	Pasteur Merieux Serums Vacc	Composition destinee a l'induction d'une reponse immunitaire mucosale
FR2732895B1 (fr) *	1995-04-11	1997-05-16	Pasteur Merieux Serums Vacc	Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
US6120794A (en) *	1995-09-26	2000-09-19	University Of Pittsburgh	Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5891994A (en) *	1997-07-11	1999-04-06	Thymon L.L.C.	Methods and compositions for impairing multiplication of HIV-1
FR2781160B1 (fr) *	1998-07-03	2000-08-18	Pasteur Merieux Serums Vacc	Utilisation d'un compose amphipathique pour adjuver un vaccin sous-unitaire
FR2783170B1 (fr) *	1998-09-11	2004-07-16	Pasteur Merieux Serums Vacc	Emulsion immunostimulante
EP1156781B1 (de) *	1999-02-26	2005-06-08	Chiron Corporation	Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln
US6558670B1 (en) *	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
EP1212085B1 (de) *	1999-08-27	2007-10-31	INEX Pharmaceuticals Corp.	Zusammensetzungen zur stimulation der zytokin sekretion und zur induktion einer immunantwort
US20050249794A1 (en) *	1999-08-27	2005-11-10	Semple Sean C	Compositions for stimulating cytokine secretion and inducing an immune response
US6399067B1 (en) *	2000-04-28	2002-06-04	Thymon L.L.C.	Methods and compositions for impairing multiplication of HIV-1

2000
- 2000-10-06 FR FR0012808A patent/FR2814958B1/fr not_active Expired - Fee Related
2001
- 2001-10-08 WO PCT/FR2001/003096 patent/WO2002028427A2/fr not_active Ceased
- 2001-10-08 AU AU2001295671A patent/AU2001295671A1/en not_active Abandoned
- 2001-10-08 AU AU2001295673A patent/AU2001295673A1/en not_active Abandoned
- 2001-10-08 AT AT01976380T patent/ATE350057T1/de active
- 2001-10-08 AT AT01976378T patent/ATE295180T1/de not_active IP Right Cessation
- 2001-10-08 EP EP01976380A patent/EP1326636B1/de not_active Expired - Lifetime
- 2001-10-08 EP EP01976378A patent/EP1326635B1/de not_active Expired - Lifetime
- 2001-10-08 PT PT01976380T patent/PT1326636E/pt unknown
- 2001-10-08 ES ES01976378T patent/ES2240526T3/es not_active Expired - Lifetime
- 2001-10-08 DE DE60110822T patent/DE60110822T2/de not_active Expired - Fee Related
- 2001-10-08 US US10/381,951 patent/US20030190326A1/en not_active Abandoned
- 2001-10-08 PT PT01976378T patent/PT1326635E/pt unknown
- 2001-10-08 DK DK01976380T patent/DK1326636T3/da active
- 2001-10-08 DE DE60125797T patent/DE60125797T2/de not_active Expired - Lifetime
- 2001-10-08 ES ES01976380T patent/ES2275738T3/es not_active Expired - Lifetime
- 2001-10-08 US US10/398,361 patent/US20040038922A1/en not_active Abandoned
- 2001-10-08 CA CA002424836A patent/CA2424836A1/en not_active Abandoned
- 2001-10-08 WO PCT/FR2001/003098 patent/WO2002028428A2/fr not_active Ceased
2004
- 2004-10-01 US US10/957,010 patent/US20050118188A1/en not_active Abandoned
2007
- 2007-01-23 CY CY20071100081T patent/CY1105943T1/el unknown

Also Published As

Publication number	Publication date
EP1326636A2 (de)	2003-07-16
CY1105943T1 (el)	2011-04-06
WO2002028427A2 (fr)	2002-04-11
US20050118188A1 (en)	2005-06-02
AU2001295671A1 (en)	2002-04-15
ES2275738T3 (es)	2007-06-16
WO2002028428A3 (fr)	2003-02-20
DE60125797T2 (de)	2007-12-06
FR2814958A1 (fr)	2002-04-12
WO2002028427A3 (fr)	2003-03-20
DE60125797D1 (de)	2007-02-15
AU2001295673A1 (en)	2002-04-15
EP1326635B1 (de)	2005-05-11
ATE295180T1 (de)	2005-05-15
US20030190326A1 (en)	2003-10-09
FR2814958B1 (fr)	2003-03-07
US20040038922A1 (en)	2004-02-26
PT1326635E (pt)	2005-08-31
EP1326635A2 (de)	2003-07-16
EP1326636B1 (de)	2007-01-03
DE60110822D1 (de)	2005-06-16
DK1326636T3 (da)	2007-04-30
PT1326636E (pt)	2007-02-28
CA2424836A1 (en)	2002-04-11
WO2002028428A2 (fr)	2002-04-11
ATE350057T1 (de)	2007-01-15
DE60110822T2 (de)	2006-05-11

Publication	Publication Date	Title
ES2240526T3 (es)	2005-10-16	Composicion farmaceutica para inmunizar contra el sida.
Okada et al.	1997	Intranasal immunization of a DNA vaccine with IL-12-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens
ES2437585T3 (es)	2014-01-13	Vesículas de tipo virosoma que comprenden antígenos derivados de gp41
ES2242954T3 (es)	2005-11-16	Vacuna genetica para el virus de la inmunodeficiencia.
Sasaki et al.	1997	Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1
ES2257072T3 (es)	2006-07-16	Composicion de vacuna antigripal.
Manocha et al.	2005	Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target
ES2348013T3 (es)	2010-11-26	Inmunización por inoculación de una unidad de transcripción de adn.
ES2416629T3 (es)	2013-08-02	Vacunas polivalentes de ADN de glicoproteína de VIH-1 primaria y procedimientos de vacunación
US8182821B2 (en)	2012-05-22	Flu vaccine admixture of mannan and flu antigen
US6749856B1 (en)	2004-06-15	Mucosal cytotoxic T lymphocyte responses
US8936789B2 (en)	2015-01-20	Immunoenhancer-linked oligomeric HIV envelope peptides
ES2339762T3 (es)	2010-05-25	Vacuna contra el vih y procedimiento de uso.
US20080095791A1 (en)	2008-04-24	Recombinant HIV-1 gp120 Immunogen with Three Different V3 Loops from Viruses of Different Clades
ES2366185T3 (es)	2011-10-18	Vacunas de péptidos sintéticas para vih: el epítopo de cbd como un inmunógeno eficaz para provocar anticuerpos ampliamente neutralizantes contra el vih.
US20230149537A1 (en)	2023-05-18	Vaccines, adjuvants, and methods of generating an immune response
ES2236941T3 (es)	2005-07-16	Respuesta mucosal linfocitos t citotoxicos.
CN102365095B (zh)	2015-11-25	分裂gp41
CN107208110A (zh)	2017-09-26	用于诱导特异性抗体和细胞免疫的dna基序化合物和方法
US20120258124A1 (en)	2012-10-11	Antigen-antibody complexes as hiv-1 vaccines
EA021191B1 (ru)	2015-04-30	НОВЫЕ АНТИГЕНЫ gp41
AU2003293733B2 (en)	2010-02-11	Novel amine-based adjuvant
ES2345198T3 (es)	2010-09-17	Composicion y procedimientos inmunologicos.
EP0328390A2 (de)	1989-08-16	Peptidbehandlung von hartnäckigen Infektionskrankheiten
Berzofsky et al.	2004	Mucosal Vaccines to Induce Cellular Immunity Against HIV and Other Viral Infections